 |
Top 10 Obesity treatment startups in USA
Updated: May 09, 2024 |
1
Funding: $1B
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
2
Funding: $544.8M
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.
3
Funding: $290M
Our purpose is to reduce the physical, emotional and economic burdens of obesity as a driver of diseases, creating value for the people we serve and the investors we work for.
Our purpose is to reduce the physical, emotional and economic burdens of obesity as a driver of diseases, creating value for the people we serve and the investors we work for.
4
Funding: $276M
Viome has developed technology aimed at balancing microorganisms in the gut. With Viome, you can fine-tune the function of your gut microbiome with a personalized diet to minimize the production of harmful metabolites and maximize the production of beneficial ones, so that you experience increased energy and general well-being, all while reaching and maintaining a healthy state of balance.
Viome has developed technology aimed at balancing microorganisms in the gut. With Viome, you can fine-tune the function of your gut microbiome with a personalized diet to minimize the production of harmful metabolites and maximize the production of beneficial ones, so that you experience increased energy and general well-being, all while reaching and maintaining a healthy state of balance.
5
Funding: $185.6M
ReShape Lifesciences is a developer of minimally invasive medical devices to treat obesity and metabolic diseases.
ReShape Lifesciences is a developer of minimally invasive medical devices to treat obesity and metabolic diseases.
6
Funding: $167M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
7
Funding: $161.2M
EnteroMedics is the developer of in-class weight loss treatments for obesity and obesity related risk factors.
EnteroMedics is the developer of in-class weight loss treatments for obesity and obesity related risk factors.
8
Funding: $150.4M
Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
9
Funding: $127.6M
Calibrate is a digital metabolic health business that provides a virtual program for weight loss.
Calibrate is a digital metabolic health business that provides a virtual program for weight loss.
10
Funding: $81.5M
USGI Medical develops technologies to enable incisionless surgeries that treat diseases through the natural passageways of the body. The goal is to reduce the size of the stomach using proprietary tissue anchors using a noninvasive, endoscopic procedure requiring no incisions.
USGI Medical develops technologies to enable incisionless surgeries that treat diseases through the natural passageways of the body. The goal is to reduce the size of the stomach using proprietary tissue anchors using a noninvasive, endoscopic procedure requiring no incisions.
Ad
Advertise your startup
11
Funding: $49.2M
ValenTx has developed the ValenTx endoluminal bypass therapy that requires no surgery, stapling or permanent modification of the obese patient's anatomy.
ValenTx has developed the ValenTx endoluminal bypass therapy that requires no surgery, stapling or permanent modification of the obese patient's anatomy.
12
Funding: $30M
Cloud Health Systems provides consultations and other health services to consumers, first focusing on metabolic health and obesity.
Cloud Health Systems provides consultations and other health services to consumers, first focusing on metabolic health and obesity.
13
Funding: $26.3M
Form Health is a telemedical weight loss company that focuses on individuals dealing with obesity.
Form Health is a telemedical weight loss company that focuses on individuals dealing with obesity.
15
Funding: $3.3M
Adipo Therapeutics is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation.
Adipo Therapeutics is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation.
16
Funding: $3.2M
Phenomix Sciences an early-stage spinout of the Mayo Clinic focused on personalized treatments for chronic diseases. Its first product tackles obesity with a novel blood-based test that is designed to accurately predict the subtype of obesity with a sensitivity and specificity >90%.
Phenomix Sciences an early-stage spinout of the Mayo Clinic focused on personalized treatments for chronic diseases. Its first product tackles obesity with a novel blood-based test that is designed to accurately predict the subtype of obesity with a sensitivity and specificity >90%.
17
Funding: $2.9M
MelliCell develops therapeutics for diabetes and obesity using a proprietary in vitro model of weight gain in human fat cells.
MelliCell develops therapeutics for diabetes and obesity using a proprietary in vitro model of weight gain in human fat cells.
18
Kintai is a biotechnology company that advancing precision therapeutics based on enteric signaling networks in the human body.
19
Phyteau is developing completely safe and effective therapeutics to give people control over their metabolism, blood sugar and weight. Our approach represents a new class of incretin-based therapy for diabetes, obesity and related metabolic conditions like NASH, NAFLD and prediabetes.